Literature DB >> 30532313

Author's reply.

Prashant Narhari1, Amber Haseeb2, Serene Lee3, Vivek Ajit Singh2.   

Abstract

Entities:  

Year:  2018        PMID: 30532313      PMCID: PMC6241065          DOI: 10.4103/ortho.IJOrtho_141_18

Source DB:  PubMed          Journal:  Indian J Orthop        ISSN: 0019-5413            Impact factor:   1.251


× No keyword cloud information.
Sir, I am pleased that you1 have shown keen interest in my manuscript.2 However, points that got my attention are as follows: (1) This case was a spontaneous transformation of a chondroblastoma (benign) to conventional osteosarcoma (malignant) in a healthy adult. The patient did not have any signs or symptoms to suggest that he was immunocompromised. I suggest some clarification to be done to emphasize that the case was a healthy adult. (2) Osteosarcomas are never associated with HIV in the past. I believe that there is no justification to screen the patient for HIV or performing a CD4 count in this patient. Even if it was done and happens to be positive, it would probably mean a mere coincidence rather than clinical association between HIV and osteosarcoma. (3) Considering point (2) above, please consider to revise the statement below: HIV infection ought to be considered in the studied patient and, hence, CD4 count and viral overload estimations were solicited to be contemplated. If these measurements were done and they showed positive HIV status, the case in question could be truly considered a novel case report. This is because osteosarcoma transformation of a chondroblastoma in HIV-positive patient has never been reported in the literature so far.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  1 in total

1.  Spontaneous Conventional Osteosarcoma Transformation of a Chondroblastoma: A Case Report and Literature Review.

Authors:  Prashant Narhari; Amber Haseeb; Serene Lee; Vivek Ajit Singh
Journal:  Indian J Orthop       Date:  2018 Jan-Feb       Impact factor: 1.251

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.